Back to Authors

Moura, Marta Casal

https://orcid.org/0000-0001-7439-6501

Mayo Clinic

Mayo Clinic

Citations 27

Thoracic Involvement in IgG4-Related Disease
Gripaldo, Ria, Baqir, Misbah , Ryu, Jay H. , Moura, Marta Casal , Ryu, Jay H

Seminars in Respiratory and Critical Care Medicine | April 12, 2020 | Volume: 41 | Issue: 02 | Pages: 202-213

10.1055/s-0039-1700995 Get It

AbstractImmunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder that has been recognized to involve virtually any organ in the body and typically manifests mass-like lesions (tumefactive). Although initial reports of this disease (autoimmune pancreatitis [AIP]) were described in the Japanese population, it has since been reported worldwide. It is most commonly seen in adults of middle age or older, more often men than women. The pathogenesis of IgG4-RD is largely unknown, but genetic factors, microorganisms, and autoimmunity are thought to play important roles. Serum IgG4 concentration is elevated in the majority of patients with IgG4-RD but is a nonspecific finding. Characteristic histopathologic features include dense lymphoplasmacytic infiltrate, fibrosis (often in storiform pattern), and obliterative phlebitis. Lung involvement in IgG4-RD was first reported in 2004 in two patients with AIP and coexisting interstitial lung disease. Since then, a wide spectrum of intrathoracic involvement has been reported and includes not only parenchymal lung diseases but also pleural, airway, vascular, and mediastinal lesions. Thoracic involvement in IgG4-RD is often found incidentally during the workup of extrathoracic lesions but can sometimes be the presenting abnormality. The diagnosis of IgG4-RD requires correlation of clinical, laboratory, imaging, and histopathologic features. Glucocorticoids are the first-line therapy but other options including B cell depletion are being investigated. IgG4-RD is generally associated with an indolent clinical course and most patients improve with glucocorticoid therapy.
290. ASTHMA CONTROL IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATED WITH RITUXIMAB
Keogh, Karina A., Volcheck, Gerald W., Baqir, Misbah , Moura, Marta Casal , Berti, Alvise , Specks, Ulrich

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez063.014 Get It

291. EFFICACY OF RITUXIMAB AND PLASMA EXCHANGE IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS WITH SEVERE RENAL DISEASE
Mira, Maria Irazabal, Thompson, Gwen , Baqir, Misbah , Ceba, Rodrigo Cartin, Ytterberg, Steven R. , Sethi, Sanjeev , Moura, Marta Casal , Eirin, Alfonso , Berti, Alvise , Winters, Jeffrey L. , Warrington, Kenneth J. , Specks, Ulrich , Fervenza, Fernando C.

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez063.015 Get It

167. PREVALENCE OF PLEURITIS AND PERICARDITIS IN ANCA-ASSOCIATED VASCULITIS
Thompson, Gwen , Bourne, Michael H. , Baqir, Misbah , Makol, Ashima , Ytterberg, Steven R. , Makol, Ashima , Moura, Marta Casal , Koster, Matthew J. , Warrington, Kenneth J. , Specks, Ulrich

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez059.044 Get It

129. RESPIRATORY INVOLVEMENT IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL AND SEROLOGICAL PREDICTORS OF LONG-TERM ASTHMA SEVERITY
Smith, R. Lane , Keogh, Karina A., Berti, Alvise , Cornec, Divi , Moura, Marta Casal , Dagna, Lorenzo , Specks, Ulrich

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez059.006 Get It

222. PREFERENTIAL BINDING TO AN UNEXPECTED EPITOPE OF A CHIMERIC RECOMBINANT PROTEINASE 3 VARIANT BY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES
Thompson, Gwen , Nelson, Darlene R. , Fussner, Lynn A. , Hummel, Amber M., Jenne, Dieter E. , Hoffman, Gary J., Kallenberg, Cees G. M., Langford, Carol A. , McCune, Joseph W., Clair, E. William St. , Ytterberg, Steven R. , Stone, John , Moura, Marta Casal , Fervenza, Fernando C. , Hoffman, Gary, Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Stone, John, Robinson, William H. , Pang, Yuan‐Ping , Specks, Ulrich

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez061.037 Get It

Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort
Berti, Alvise , Gall, Émilie Cornec-Le , Matteson, Eric L. , Crowson, Cynthia S. , Ravindran, Aishwarya , Sethi, Sanjeev , Cornec-Le Gall, Emilie, Cornec, Divi, Casal Moura, Marta, Ravindran, Aishwarya , Berti, Alvise , Cornec, Divi , Moura, Marta Casal , Fervenza, Fernando C. , Specks, Ulrich , Cornec-Le Gall, Emilie

Nephrology Dialysis Transplantation | July 10, 2018 | Volume: 34 | Issue: 9 | Pages: 1508-1517

10.1093/ndt/gfy250 Get It

Abstract Background True population-based clinical and outcomes data are lacking for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (AAGN). Therefore we aimed to estimate the incidence, prevalence and mortality of AAGN, as well as the relationship between the grade of chronic renal damage at presentation and renal and non-renal outcomes. Methods Patients with AAGN were identified among a population-based incident cohort of 57 Olmsted County residents diagnosed with ANCA-associated vasculitis (AAV) in 1996–2015. Incidence rates were age and sex adjusted to the 2010 US white population. Age- and sex-adjusted prevalence was calculated for 1 January 2015. Survival rates were compared with expected rates in the Minnesota population. Chronic renal damage was assessed by chronicity score (CS) on biopsies performed at diagnosis. Results Thirty-four (60%) patients had AAGN. Of these, 65% had microscopic polyangiitis (MPA) and 74% were myeloperoxidase (MPO)-ANCA positive. The annual incidence of AAGN was 2.0/100 000 population [95% confidence interval (CI) 1.3–2.7] and the overall prevalence was 35/100 000 (95% CI 24–47). Mortality for AAGN was increased (P < 0.001), whereas mortality for AAV without glomerulonephritis did not differ from the general population. Minimal to mild CS predicted recovery of renal function at 1 year; clinical diagnosis (granulomatosis with polyangiitis versus MPA) and ANCA specificity (proteinase 3 versus MPO) did not. This observation was replicated in an independent cohort of 38 newly diagnosed AAGN patients seen at our centre over the 1999–2014 period. Conclusions The annual incidence and prevalence of AAGN in Minnesota are 2.0/100 000 and 35/100 000, respectively. Mortality is worse compared with AAV patients without glomerulonephritis. More advanced renal damage at diagnosis predicts less renal recovery.